PureTech Health plc (PTCHF) stock
PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY
$1.48+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
PureTech Health r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $56.57M, down 18.6% from the year before. The highest annual figure on record is $152.43M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.57M | -18.6% |
| FY2024 | Dec 31, 2024 | $69.45M | -27.8% |
| FY2023 | Dec 31, 2023 | $96.24M | -36.9% |
| FY2022 | Dec 31, 2022 | $152.43M | +38.0% |
| FY2021 | Dec 31, 2021 | $110.47M | +35.0% |
| FY2020 | Dec 31, 2020 | $81.86M | -4.6% |
| FY2019 | Dec 31, 2019 | $85.85M | +10.9% |
| FY2018 | Dec 31, 2018 | $77.40M | – |
See a number that looks wrong?